These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1476754)

  • 1. Breast cancer-associated antigen CA 15.3 in liver cirrhosis.
    Collazos J; Genolla J; Ruibal A
    Acta Oncol; 1992; 31(7):741-4. PubMed ID: 1476754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the tumor marker carbohydrate antigen 50 in liver cirrhosis. Pathogenetic considerations.
    Collazos J; Genolla J; Ruibal A
    Clin Nucl Med; 1993 Jan; 18(1):56-9. PubMed ID: 8422722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and laboratory evaluation of CA 19-9 in cirrhotic patients.
    Collazos J
    Eur J Med; 1992; 1(4):215-8. PubMed ID: 1341447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA 15.3 in nonmalignant liver diseases.
    Collazos J; Genollá J; Ruibal A
    Int J Biol Markers; 1991; 6(3):188-92. PubMed ID: 1791313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases.
    Molina R; Filella X; Bruix J; Mengual P; Bosch J; Calvet X; Jo J; Ballesta AM
    Clin Chem; 1991 Aug; 37(8):1379-83. PubMed ID: 1868598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis.
    Fabris C; Basso DA; Leandro G; Meggiato T; Elba S; Panozzo MP; Del Favero G; Fogar P; Di Mario F; Naccarato R
    Cancer; 1991 Oct; 68(8):1795-8. PubMed ID: 1717126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cancer antigen 125 as a marker of ascites in patients with liver cirrhosis].
    Jabłkowski M; Białkowska J; Koktysz R; Bartkowiak J; Stankiewicz W; Dworniak D
    Pol Merkur Lekarski; 2004; 17 Suppl 1():149-52. PubMed ID: 15603376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histocompatibility antigens, autoantibodies, and immunoglobulins in alcoholic liver disease.
    Bailey RJ; Krasner N; Eddleston AL; Williams R; Tee DE; Doniach D; Kennedy LA; Batchelor JR
    Br Med J; 1976 Sep; 2(6038):727-9. PubMed ID: 1086118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.
    Schöniger-Hekele M; Müller C
    Dig Dis Sci; 2006 Feb; 51(2):338-45. PubMed ID: 16534678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer antigen 125 levels in serum can predict the recurrence of ascites in patients with cirrhosis of the liver.
    Aguilar-Reina J; Rey-Romero C; Ortega-Viñas M; Hernandez-Pascual A; Sayago-Mota M
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():163-5. PubMed ID: 2083930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma.
    Haglund C; Lindgren J; Roberts PJ; Nordling S
    Br J Cancer; 1991 Mar; 63(3):386-9. PubMed ID: 1848439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Carbohydrate antigens CA 19-9, CA 242, CA 50 in liver diseases].
    Nowak J; Jakubowska D; Wiczkowski A; Sprzaczkowska K; Stechły T; Zmudziński W; Grzesik P; Walas R; Jarzab B
    Wiad Lek; 1998; 51(11-12):484-91. PubMed ID: 10222840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis.
    Papp M; Sipeki N; Vitalis Z; Tornai T; Altorjay I; Tornai I; Udvardy M; Fechner K; Jacobsen S; Teegen B; Sumegi A; Veres G; Lakatos PL; Kappelmayer J; Antal-Szalmas P
    J Hepatol; 2013 Sep; 59(3):457-66. PubMed ID: 23639483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do CA 19-9 and TPA play a minor role as compared to AFP in diagnosing primary hepatocellular carcinoma?
    Leandro G; Zizzari S; Fabris C; Basso D; Elba S; Del Favero G; Meggiato T; Angonese C; Di Mario F; Manghisi OG
    Oncology; 1989; 46(6):381-5. PubMed ID: 2479897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients.
    Collazos J; Genollà J; Ruibal A
    Int J Biol Markers; 1992; 7(4):244-8. PubMed ID: 1491181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis.
    Zuckerman E; Lanir A; Sabo E; Rosenvald-Zuckerman T; Matter I; Yeshurun D; Eldar S
    Am J Gastroenterol; 1999 Jun; 94(6):1613-8. PubMed ID: 10364033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
    Collazos J; Genolla J; Ruibal A
    Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum immunoglobulin A changes in alcoholic patients.
    Iturriaga H; Pereda T; Estévez A; Ugarte G
    Ann Clin Res; 1977 Feb; 9(1):39-43. PubMed ID: 883755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2014 May; 60(5):1055-62. PubMed ID: 24445215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of CA 125 in patients with benign and malignant ascites.
    Bergmann JF; Bidart JM; George M; Beaugrand M; Levy VG; Bohuon C
    Cancer; 1987 Jan; 59(2):213-7. PubMed ID: 3026603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.